Novo Nordisk's Cardiovascular Drug Candidate Ziltivekimab Fails Phase 3 Trial

Novo Nordisk announced that its cardiovascular drug candidate, ziltivekimab, failed to meet its primary endpoint in a Phase 3 clinical trial, not significantly reducing major adverse cardiovascular events (MACE) compared to placebo. While some inflammation-related biomarkers improved, this did not translate into a reduction in actual cardiovascular events. Serious infections were more frequent in the ziltivekimab group.